Navigation Links
Neurology in Biological Technology

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

... disease at the 2009 American Academy of neurology meeting in Seattle, WA. The NuroPro tests help ... Marcopoulou, M.D., Assistant Professor of neurology at the University of Thessaly, Greece, gave a ... includes Stanley H. Appel, M.D. Chair of neurology at Methodist Neurological Research Institute in ...

BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer

... industry with specific expertise in building neurology assets for success. The two will serve in ... and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical ... corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical ...

The Parkinson's Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinson's Disease

... Fahn, M.D., the H. Houston Merritt Professor of neurology and Director of the Center for Parkinson's ... is led by Lucien Cte, M.D., Professor of neurology at Columbia University, and Karen Marder, M.D., M.P.H., the Sally Kerlin Professor of neurology at Columbia University. "With a disease like ...

Avicena Appoints Dr. M. Flint Beal to Board of Directors

... professor and chairman of the department of neurology and neuroscience at the Weill Medical College at Cornell University, and director of neurology at New York Presbyterian Hospital. Prior to Cornell, Dr. Beal was the professor of neurology at the Harvard Medical School and chief of the ...

NeurogesX Reports Second Quarter 2008 Results

... - Phase 1 clinical trial of NGX-1998 initiated - Journal neurology published positive Phase 3 data on NGX-4010 in HIV-DSP SAN MATEO, ... Phase 2 study in 2009. During the second quarter of 2008, the journal neurology published data from NeurogesX' Phase 3 pivotal trial (C107) in patients ...

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

... data from this trial next year," said Dr. Mark Freedman, Professor of neurology at the University of Ottawa and Director of the MS Research Clinic at the ... with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to ...

Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals

... it to market. Dr. Katz also served as Professor of Ophthalmology, neurology and Neurosurgery, and as the Chairman of the Department of Ophthalmology ... University of California at San Francisco after completing residencies in neurology at Harvard Medical School and in Ophthalmology at Tufts-New England ...

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

... led by Dr. Steven Hersch, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed an oxidative damage marker, 8OH2DG, which ... General Hospital, were published in the January 24, 2006 issue of neurology and showed that HD-02 suppressed a Huntington's disease marker. Some ...

Amarin Signs Agreement to Acquire Ester Neurosciences

... Adds Promising Phase II neurology Candidate $8.1 Million Financing in Connection With Acquisition ... advancing Ester's programs along with our existing development pipeline in neurology and cardiovascular disease." Eli Hazum, Chief Executive Officer of Ester ...

Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer

... residencies in pediatrics at New York University School of Medicine and in neurology at Harvard Medical School. Dr. Siffert was certified by the American Board of neurology and Psychiatry. He holds an M.D. degree from the University of Sao Paulo ...

New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain

... et al. Neurogastroenterol Motil 2004; 16: 383-394,5 (5) Gimbel JS et al. neurology 2003; 60: 927-934 (6) Watson CP et al. neurology 1998; 50 : 1837-1841 (7) Staahl C et al. Differential effect of opioids ...

Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease

... and the burden on caregivers," said study investigator, Daniel Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and Behavior neurology Program with the Department of Neurological Sciences at the University of Nebraska Medical Center . "This information shows that not only are AD ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... stem cell-based screens and assays. Dr. Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a professor of neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on ...

New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline

... candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic ...

iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board

... iPS technology to the development of new therapeutics for unmet medical needs. We will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said ...

Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study

... specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com . FORWARD-LOOKING STATEMENTS This press release ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of neurology (AAN) meeting in Seattle, Washington. These posters, titled "Neurologic Safety of Treatment with NGX-4010, a High-Concentration Capsaicin Patch, in ...

Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...

Medivation Announces Upcoming Scientific Presentations at Medical Conferences

... MDV3100 on Sunday, April 26, at 4:00 p.m. Central Time (POD17. Prostate Cancer: Advanced Dimebon 61st American Academy of neurology (AAN) Annual Meeting, April 25 - May 2, Seattle Two poster presentations featuring Dimebon that will take place on: ...

Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development

... development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablation prior to bone marrow transplantation. Pharmalink also seeks ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... Immunex Corporation from 1999 - 2001. In that capacity, he managed the discovery, development, manufacture and marketing for Immunex oncology and neurology products. Mr. Parker received his undergraduate degree in Biological Sciences from the University of Chicago , an MBA from the University of ...

Alpine Biomed Opens New Manufacturing Facility to Support Demand for Specialty Diagnostic Devices

... devices in the industry." About Alpine Biomed Alpine Biomed is a global leader in specialty diagnostic devices for the gastroenterology and neurology clinical markets. The company produces diagnostic tools used for gastroesophageal reflux disease (GERD), commonly referred to as acid reflux disease, ...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

... and T cells. The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types ...

NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations

... at the University of California, San Diego . Prior to that, he held research positions at the Neuropsychology Laboratory at the Salk Institute, the neurology Department at the Medical School of the University of California at Irvine , and the Cognitive Psychophysiology Laboratory at the University ...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy

... of living with uncontrolled seizures," said lead study author Professor Peter Halasz, MD, PhD, National Institute of Psychiatry and Neurology, neurology Department, Budapest. "Vimpat(R) showed significant efficacy versus placebo in a challenging clinical trial patient population." In the study, ...

Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.

... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . (Logo: ...

Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations

... is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private Securities ...

Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz

... of Cincinnati , his M.D. from Vanderbilt University and his neurosurgical training at Baylor College of Medicine . Dr. Waltz also had training in neurology at The National Hospital for Neurological Diseases and in Neuropathology at Oxford University , both in the U.K. About Peregrine ...

Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia

... needs worldwide. The company's major therapeutic areas of focus include hematology, oncology, infectious disease, obesity and metabolic disorders, neurology and psychiatry, pain and women's health. About Janssen Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., based in ...

Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million

... pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com . About Dow Dow Pharmaceutical Sciences, ....

The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy

... to seek stem cell treatments," said Dr. Olle Lindvall, co-chair of the ISSCR task force that developed the guidelines and professor in clinical neurology at the University of Lund. "Stem cell research holds tremendous promise for the development of novel therapies for many serious diseases. However, ...

Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe

... 37 per cent. Out of the 260 cancer compounds in clinical development in Europe, Denmark accounts for 17 per cent of the European pipeline. neurology (15 per cent) and inflammation/autoimmune diseases (14 per cent) are the fields with second and third most Danish compounds in clinical trials. ...

ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia

... About Avineuro Pharmaceuticals, Inc.: Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug ...

Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference

... Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com . "Safe Harbor" Statement under the Private ...

The Lancet's New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily

... and easy access to daily online first research published across The Lancet journals (The Lancet, The Lancet Infectious Diseases, The Lancet neurology and The Lancet Oncology). - Free access to exclusive online-only editorial analysis of how the most important published research impacts ...

Global Psychiatrists Unite to Improve Services in Mental Health

... Dr Wolfgang Fleischhacker, Medical University Innsbruck, Austria Dr Marcelo Cetkovich-Bakmas, the Department of Psychiatry, Institute of Cognitive neurology (INECO), and the Department of Psychiatry, Institute of Neurosciences, Favaloro Foundation, Buenos Aires, Argentina Dr Marc De Hert, University ...

BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...

Dr. Yong Shi awarded NSF grant

... on the project are Professor Sundeep Mangla (M. D., Director of Interventional Neuroradiology , Associate Professor of Radiology, Neurosurgery, and neurology ) and Professor Ming Zhang (M.D, Assistant Professor, Dept of Anesthesiology), both from SUNY Downstate Medical Center at Brooklyn, New York. ...

Molecular Biometrics Announces Results of Parkinson's Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology

... Faculty of Medicine, Department of Neurology and Neurosurgery, and Department of Medicine, McGill University, and member of the Attending Staff in neurology at Sir Mortimer B. Davis - Jewish General Hospital, in Montreal, Canada. "This proof-of-concept gives us great hope that biospectroscopy will offer a ...

BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial

... The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients ...
Other Contents
(Date:7/23/2014)... that has the entire country in its grip is affecting ... be responsible for the proliferation of a heat-loving amoeba commonly ... hot springs, which the drought has made warmer than usual ... an infection caused by this parasite after swimming in several ... of an individual and travels to the brain. Nose plugs ...
(Date:7/23/2014)... The planet,s soil releases about 60 billion tons of ... more than that released by burning fossil fuels. This ... release of carbon is balanced by carbon coming into ... matter, as well as by the underground activities of ... that rising temperatures increase the rate of soil respiration. ...
(Date:7/23/2014)... Non-biting blow fly Chrysomya megacephala is commonly ... investigations to determine the time of death, referred to ... derived form of C. megacephala from Tamil ... morphological features and molecular characterization through generation of DNA ... in the open access Biodiversity Data Journal . ...
Breaking Biology News(10 mins):Diseases of another kind 2Climate change and the soil 2Dead body feeding larvae useful in forensic investigations 2
(Date:7/23/2014)... (PRWEB) July 23, 2014 Obtaining insurance ... for the average consumer. The Quotes Pros company is ... all 50 states this year to make research faster ... are issuing the rates information are actual agencies that ... underwritten inside the U.S. An advantage to adults who ...
(Date:7/23/2014)... July 23, 2014 The National ... today a robust trial for a defined period ... risk adjusting relevant quality measures for sociodemographic factors, ... policy.     , Sociodemographic factors can be socioeconomic, e.g., ... ethnicity, and primary language. Growing evidence shows ...
(Date:7/23/2014)... Edmond, Oklahoma (PRWEB) July 23, 2014 ... North America’s leading provider of in-home care for ... Healthy Longevity Webinar Series featuring experts in a ... upcoming webinar will feature licensed clinical social worker ... the most common causes of caregiver stress and ...
(Date:7/23/2014)... 23, 2014 A new study has ... morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive hysterectomies ... a woman’s body, Bernstein Liebhard LLP reports. The research, ... of the American Medical Association, looked at 36,000 women ... 500 U.S. hospitals from 2006 to 2012. Ninety-nine of ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Prices for All 50 States Now Explored at Insurer Website 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 2Health News:Oklahoma Home Care Assistance Hosting Caregiver Mindfulness Webinar Tomorrow 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3
Other TagsOther Tags